FDA Weighs Giredestrant as Adjuvant Therapy for Early Breast Cancer

Summary: The FDA is looking at a new daily pill called giredestrant to help treat early-stage breast cancer. It is specifically for adults with a type of cancer known as ER-positive, HER2-negative. In a large study with over 4,100 patients, this new pill worked better than standard treatments. It lowered the chance of the cancer coming back by 30%. After three years, over 92% of patients taking it were still alive and cancer-free. Doctors say this is the biggest update for this type of breast cancer treatment in decades! The FDA will make its final decision by November 2026.

For more details, see rssapp-empr-com at empr.com/news/fda-priority-review-giredestrant-breast-cancer/ (opens in new tab)